Optune Lua is FDA approved for use with immunotherapy or docetaxel in metastatic stage IV NSCLC post-platinum treatment. The device uses tumor treating fields to disrupt cancer cell division, offering ...
(RTTNews) - Novocure (NVCR) an oncology company, has received approval from the FDA for its new Head Flexible Electrode transducer arrays, designed for use with its Optune Gio device, which is used in ...
FDA approved Optune Pax with gemcitabine/nab-paclitaxel, applying alternating electric fields to disrupt mitosis via abdominal arrays, expanding noninvasive, home ...
For the first time in 30 years, the Food and Drug Administration has approved a new treatment for an inoperable type of pancreatic cancer.
Zacks Investment Research on MSN
Novocure's Optune Lua gets Japan reimbursement for NSCLC treatment
Novocure NVCR recently announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune ...
Lung cancer can be treated with small molecules formulated as pills as well as biological medications that are injected or infused, both as standalone treatments or as part of drug combinations. A ...
The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell lung cancer (NSCLC). The device utilizes portable transducer arrays placed on ...
Novocure NVCR recently announced the FDA approval for its portable therapeutic device, Optune Pax, for treating adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and ...
In early February 2026, NovoCure announced that the U.S. FDA had approved its Optune Pax device for use with gemcitabine and nab-paclitaxel in adults with locally advanced pancreatic cancer, following ...
Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer Phase 3 PANOVA-3 trial showed a ...
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its new Head Flexible Electrode (HFE) transducer arrays for use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results